Evodiamine may inhibit insulin resistance in type 2 diabetes through IRS-1/PI3K/AKT/GLUT4 pathway
Abstract
This research aimed to elucidate the potential therapeutic efficacy of evodiamine (Evo) in alleviating IR associated with T2DM, and to further explain its underlying mechanism. The candidate bioactive components and targets of EVO were identified by using biomedical databases. Targets associated with IR were acquired from various databases. Intersectional analysis of Evo-related and IR-specific targets facilitated the construction of a PPI network. Cytoscape software was employed for the visualization of the "compound-target-disease" interactions, enabling the identification of key proteins. GO and KEGG analyses were then carried out to clarify the biological roles of the core Evo targets. MD analysis further confirmed the interactions between Evo and these key proteins. Additionally, the CCK-8 assay evaluated the influence of Evo on cell viability. The effects of Evo on glucose uptake and release were quantified, while Western blotting (WB) was employed to identify changes in protein expression driving the IRS-1/PI3K/AKT/GLUT4 signaling pathway. Furthermore, immunofluorescence techniques were implemented to visualize and quantify the expression levels of IRS-1, phosphorylated IRS-1 (p-IRS-1), and GLUT4 in insulin-resistant HepG2 cells. A total of 122 Evo-associated targets were obtained, among which 37 intersected with IR-related targets. Notably, AKT1, STAT3, SRC, and PTGS2 were identified as crucial proteins within this network. KEGG pathway analysis revealed enrichment…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.